Hidradenitis suppurativa: a comprehensive review of pathogenetic mechanisms, clinical phenotypes, and evolving therapeutic paradigms
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20261942Keywords:
Hidradenitis suppurativa, Acne inversa, Follicular occlusion, Interleukin-17, Tumor necrosis factor-alpha, Dysbiosis, Hurley staging, Adalimumab, Biologic therapy, Systemic comorbidityAbstract
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent, and debilitating inflammatory skin condition characterized by deep-seated nodules, abscesses, fistulating sinus tracts, and scarring, primarily affecting apocrine gland-bearing skin. Historically dismissed as a disorder of poor hygiene or mere follicular occlusion, contemporary research has redefined HS as a systemic immune-mediated disease with profound implications for patient quality of life and metabolic comorbidities. This exhaustive review synthesizes the most current understanding of HS pathogenesis, which is now recognized as a multifactorial interplay of genetic predisposition, follicular hyperkeratosis and occlusion, dysbiosis of the cutaneous microbiome, and a profound dysregulation of the innate and adaptive immune system, with a prominent role for interleukin (IL)-17, IL-1β, and tumor necrosis factor-alpha (TNF-α). We meticulously detail the clinical spectrum, from prodromal manifestations to advanced Hurley stage III disease, emphasizing the nuances of phenotype classification and the critical importance of early diagnosis to mitigate disease-associated morbidity. A principal focus is dedicated to the rapidly expanding therapeutic landscape, moving beyond traditional antibiotics and surgery to include biologic agents that target specific inflammatory cytokines, with adalimumab (anti-TNF) as a cornerstone and emerging evidence for secukinumab (anti-IL-17A) and apremilast (PDE4 inhibitor). We further examine the robust association of HS with cardiometabolic syndrome, inflammatory bowel disease, and psychiatric comorbidities, advocating for a holistic, multidisciplinary management approach. This review consolidates evidence from recent clinical trials, consensus guidelines, and mechanistic studies to provide a foundational resource for clinicians and researchers navigating the complexities of this challenging disease.
References
Chen W, Plewig G. Should hidradenitis suppurativa/acne inversa best be renamed as “dissecting terminal hair folliculitis”? Exp Dermatol. 2017;26(6):544-7. DOI: https://doi.org/10.1111/exd.13211
Kimball AB, Kirby J, Ingram JR, Tran T, Pansar I, Ciaravino V, et al. Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes. Dermatol Ther. 2024;14(1):83-98. DOI: https://doi.org/10.1007/s13555-023-01085-w
Shavit E, Alavi A, Bechara FG, Bennett RG, Bourcier M, Cibotti R, et al. Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017. Exp Dermatol. 2019;28(1):94-103. DOI: https://doi.org/10.1111/exd.13849
Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol. 2017;153(8):760. DOI: https://doi.org/10.1001/jamadermatol.2017.0201
Zouboulis CC, Nogueira Da Costa A, Fimmel S, Zouboulis KC. Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific. J Eur Acad Dermatol Venereol. 2020;34(7):1555-63. DOI: https://doi.org/10.1111/jdv.16264
Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad Dermatol. 2015;73(5):S8-11. DOI: https://doi.org/10.1016/j.jaad.2015.07.045
Johnston LA, Alhusayen R, Bourcier M, Delorme I, George R, O’Brien E, et al. Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update. J Cutan Med Surg. 2022;26:2S-24S. DOI: https://doi.org/10.1177/12034754221116115
Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos‐Bourboulis EJ, Fabbrocini G, et al. What causes hidradenitis suppurativa?-15 years after. Exp Dermatol. 2020;29(12):1154-70. DOI: https://doi.org/10.1111/exd.14214
Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917-24. DOI: https://doi.org/10.1111/bjd.16101
Jfri A, Netchiporouk E, Raymond K, Litvinov IV, O’Brien E. Association of clinical severity scores with psychosocial impact in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2021;84(6):1712–5. DOI: https://doi.org/10.1016/j.jaad.2020.08.022
Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2(1):9-16. DOI: https://doi.org/10.4161/derm.2.1.12490
Nikolakis G, Kaleta KP, Vaiopoulos AG, Wolter K, Baroud S, Wojas-Pelc A, et al. Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review. Dermatology. 2021;237(5):673-97. DOI: https://doi.org/10.1159/000509873
Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366-76. DOI: https://doi.org/10.1016/j.jaad.2019.06.1301
Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1):5. DOI: https://doi.org/10.1186/s41073-019-0064-8
Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50-61. DOI: https://doi.org/10.1111/jdv.16677
Alotaibi HM. Incidence, Risk Factors, and Prognosis of Hidradenitis Suppurativa Across the Globe: Insights from the Literature. Clin Cosmet Investig Dermatol. 2023;16:545-52. DOI: https://doi.org/10.2147/CCID.S402453
Bukvić Mokos Z, Miše J, Balić A, Marinović B. Understanding the Relationship Between Smoking and Hidradenitis Suppurativa. Acta Dermatovenerol Croat ADC. 2020;28(1):9-13.
Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: A review of the literature. Int J Womens Dermatol. 2019;5(5):330-4. DOI: https://doi.org/10.1016/j.ijwd.2019.06.026
Jenkins T, Isaac J, Edwards A, Okoye GA. Hidradenitis Suppurativa. Dermatol Clin. 2023;41(3):471-9. DOI: https://doi.org/10.1016/j.det.2023.02.001